CaSR

Effects of intra-synovial injections of CaSR antagonist (NPS2143) and agonist (Cinacalcet) on morphology (A) in rat TMJ cartilage without (Control) or with UAC stimulation. Test compounds (50 μL of 100 nM stock) and vehicle injections were performed on 10‐week‐old rats every other day for 4 weeks. UAC began 4 weeks before drug injections and continued for another 4 weeks during drug treatments. (A) Safranin O staining (in red) showed the ability of NPS2143 to increase proteoglycan content and thickness of TMJ cartilage and decreased OA grade, the ability of Cinacalcet to suppress these parameters in both control and UAC groups when compared with corresponding vehicle‐injected group. Scale bar = 100 µm. n = 6 rats per group.

The effects of a GPRC6A inhibitor on testosterone-induced ROS generation. Cells were pretreated with the GPRC6A inhibitor, NPS2143 (1 uM), for 30 min and ROS generation was monitored after 5 min of testosterone treatment. Data are presented as mean ?S.E. (n = 4).

Effects of intra-synovial injections of CaSR antagonist (NPS2143) and agonist (Cinacalcet) on morphology (A) in rat TMJ cartilage without (Control) or with UAC stimulation. Test compounds (50 μL of 100 nM stock) and vehicle injections were performed on 10‐week‐old rats every other day for 4 weeks. UAC began 4 weeks before drug injections and continued for another 4 weeks during drug treatments. (A) Safranin O staining (in red) showed the ability of NPS2143 to increase proteoglycan content and thickness of TMJ cartilage and decreased OA grade, the ability of Cinacalcet to suppress these parameters in both control and UAC groups when compared with corresponding vehicle‐injected group. Scale bar = 100 µm. n = 6 rats per group.

The effects of a GPRC6A inhibitor on testosterone-induced ROS generation. Cells were pretreated with the GPRC6A inhibitor, NPS2143 (1 uM), for 30 min and ROS generation was monitored after 5 min of testosterone treatment. Data are presented as mean ?S.E. (n = 4).